SCHEMBL285589

SCHEMBL285589

CCCc1noc(C)c1C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
CACNA1F O60840 2/20 0.42
CACNA1D Q01668 2/20 0.42
CACNA1S Q13698 2/20 0.42
CACNA1C Q13936 2/20 0.42
HSP90AA1 P07900 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
PDE4D Q08499 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL108853 0.90 ALDH1A1 (0.42) ALDH1A1L3MBTL1CACNA1FCACNA1DCACNA1S
SCHEMBL860192 0.86 L3MBTL1 (0.54) ALDH1A1L3MBTL1SMN1; SMN2NPSR1TDP1
SCHEMBL11570115 0.84 HSP90AA1 (0.47) ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL23641869 0.83 ALDH1A1 (0.45) ALDH1A1L3MBTL1CACNA1FCACNA1DCACNA1S
SCHEMBL285703 0.83 MLYCD (0.40) ALDH1A1L3MBTL1CACNA1FCACNA1DCACNA1S
SCHEMBL11551455 0.81 NPC1 (0.55) L3MBTL1SMN1; SMN2POLBTDP1
SCHEMBL11552443 0.81 MAPT (0.46) ALDH1A1L3MBTL1LMNAHTTSMN1; SMN2
SCHEMBL10981784 0.81 NPC1 (0.40) ALDH1A1LMNAHTTSMN1; SMN2NPSR1
SCHEMBL11553215 0.79 SLC26A6 (0.50) ALDH1A1LMNAHTTNPSR1MEN1
SCHEMBL11558964 0.79 NPC1 (0.53) L3MBTL1SMN1; SMN2POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427457-B1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS HOFFMANN LA ROCHE (CH) 2013-07-17 EP disclosed
US-8357703-B2 Pyridines HOFFMANN-LA ROCHE INC. (US) 2013-01-22 US disclosed
EP-2427457-A1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
US-20100286117-A1 PYRIDINES ROCHE PALO ALTO LLC 2010-11-11 US disclosed
WO-2010127978-A1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286117-A1 PYRIDINES GABRA5, GABRA1, GABRA4 ALDH1A1 459/4885L3MBTL1 4747/4885CACNA1F 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.